valganciclovir 450 MG Oral Tablet

Known as: VALGANCICLOVIR HCL 450MG TAB, valGANciclovir HCl 450 MG Oral Tablet, VALGANCICLOVIR HYDROCHLORIDE 450 mg ORAL TABLET, FILM COATED 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2018
012320012018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Cytomegalovirus (CMV) remains an important pathogen in solid organ transplant patients. OBJECTIVE We executed a… (More)
Is this relevant?
2015
2015
OBJECTIVE We compared the effectiveness of lower-dose (LD) (450 mg/day for 6 months) to standard-dose (SD) (900 mg/day for 6… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2012
2012
BACKGROUND Cytomegalovirus (CMV) prevention can be achieved by prophylaxis or preemptive therapy. We performed a prospective… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Cytomegalovirus (CMV) is the most prevalent opportunistic infection after lung transplantation. Current strategies do… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2010
2010
BACKGROUND Drug-resistant cytomegalovirus (CMV) infections can cause significant morbidity among high-risk transplant recipients… (More)
  • table 1
  • table 2
Is this relevant?
2006
2006
The pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir were compared in allogeneic stem… (More)
Is this relevant?
2004
2004
We investigated the emergence of cytomegalovirus (CMV) ganciclovir-resistance mutations in 301 high-risk solid-organ transplant… (More)
Is this relevant?
2004
2004
We investigated retrospectively the risk factors for cytomegalovirus (CMV) infection under ganciclovir or valganciclovir… (More)
Is this relevant?
2003
2003
The clinical patterns and predictors of cytomegalovirus (CMV) disease in kidney and/or pancreas transplant patients on… (More)
Is this relevant?
2001
2001
▴ Valganciclovir is a prodrug of ganciclovir which has been developed for the treatment of cytomegalovirus (CMV) retinitis in… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?